- Stephen Ayers upgrades AbbVie (ABBV, Financial) to a buy, noting a 10% undervaluation.
- AbbVie offers a strong dividend yield of 3.73%, presenting an appealing risk/reward.
- Analysts predict a potential 27.19% upside with a price target of $214.76.
Stephen Ayers has elevated his rating for AbbVie Inc (ABBV) from hold to buy, underscoring a roughly 10% undervaluation based on a discounted cash flow analysis. The stock is further supported by an enticing dividend yield of 3.73%, making it an attractive opportunity for investors seeking a balanced risk/reward profile.
Wall Street Analysts Forecast
According to projections from 24 analysts, the average one-year price target for AbbVie Inc (ABBV, Financial) stands at $214.76. Estimates range from a high of $251.00 to a low of $173.00. This average target suggests a significant potential upside of 27.19% from the current trading price of $168.86. For more detailed estimates, visit the AbbVie Inc (ABBV) Forecast page.
The consensus recommendation from 27 brokerage firms positions AbbVie Inc's (ABBV, Financial) average brokerage recommendation at 2.0, indicating an "Outperform" status. The rating scale, ranging from 1 to 5, defines 1 as a Strong Buy and 5 as a Sell.
Understanding the GF Value Estimate
According to GuruFocus, the estimated GF Value for AbbVie Inc (ABBV, Financial) in one year is $167.96, which indicates a slight downside of 0.53% from the current price of $168.86. The GF Value represents GuruFocus' assessment of the fair value for the stock, calculated based on historic trading multiples, past business growth, and future business performance estimates. To explore more detailed information, visit the AbbVie Inc (ABBV) Summary page.
